Profile of INDIA GLOBALIZATION CAPITAL(NYSEARCA:IGC) stock

INDIA GLOBALIZATION CAPITAL0.4146

NYSEARCA:IGC (2/3/2023, 7:04:00 PM)+0.01 (+3.65%)

After market: 0.42 +0.01 (+1.3%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS Sector	Industrials
GICS Industry	Trading Companies & Distributors

Chartmill FA Rating

Valuation		Growth
Profitability		Health
Dividend

Overview

Earnings (Last)	N/A N/A	Earnings (Next)	02-08 2023-02-08/amc
Ins Owners	9.25%	Inst Owners	9.42%
Market Cap	22.00M	Shares	53.07M
PE	N/A	Fwd PE	N/A
Dividend Yield	N/A	Analysts	N/A
IPO	04-13 2006-04-13

Stock Screener Links

American Stock Exchange Stock Screener

Find more stocks on American Stock Exchange

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

India Globalization Capital, Inc. engages in the development and commercialization of cannabinoid based alternative therapies for indications, such as Alzheimer's disease, Parkinson's disease, and pain. The company is headquartered in Potomac, Maryland and currently employs 52 full-time employees. The company went IPO on 2006-04-13. The firm's segments include Life Sciences and Infrastructure. The Life Sciences segment operates primarily through wholly owned subsidiaries, including IGC Pharma LLC, a clinical-stage biopharmaceutical company based in Maryland. The purpose of IGC Pharma LLC is to treat Alzheimer's patients and alleviate caregiver burden. The Life Sciences segment also includes the development of over-the-counter personal care products, operated by certain of the Company's subsidiaries under various brands. The Infrastructure segment involves the execution of construction contracts and the rental of heavy construction equipment. The company has two main investigational drug assets, which are IGC-AD1 and TGR-63. Its lead therapeutic candidate, IGC-AD1 is in Phase II trials for treating agitation in dementia from Alzheimer's and TGR-63, an enzyme inhibitor to reduce neurotoxicity in Alzheimer's cell lines.